Company: CERO
Filing Date: 2025-08-22
Form Type: 10-Q
Source: 0001213900-25-079898
Chunk: 300

Company: CERO THERAPEUTICS HOLDINGS, INC.
Filing Date: 2025-08-22
Form: 10-Q
Item: Item 2
Chunk 300
---
-K/A filed by CERo Therapeutics Holdings, Inc. with the Securities and Exchange Commission on February 27, 2024).

    3.3
     
    Certificate
    of Amendment to the Second Amended and Restated Certificate of Incorporation (incorporated by reference to Exhibit 3.1 to the Current
    Report on Form 8-K filed by CERo Therapeutics Holdings, Inc. with the Securities and Exchange Commission on January 6, 2025).

    3.4†
     
    Certificate
    of Designation of Preferences, Rights and Limitations of the Series D Convertible Preferred Stock (incorporated by reference to Exhibit
    3.1 to the Current Report on Form 8-K filed by CERo Therapeutics Holdings, Inc. with the Securities and Exchange Commission on April
    25, 2025).

    3.5
     
    Certificate
    of Amendment to the Second Amended and Restated Certificate of Incorporation of CERo Therapeutics Holdings, Inc. (incorporated by
    reference to Exhibit 3.1 to the Current Report on Form 8-K filed by CERo Therapeutics Holdings, Inc. with the Securities and Exchange
    Commission on June 11, 2025).

    4.1
     
    Form
    of Common Warrant (incorporated by reference to Exhibit 4.1 to the Current Report on Form 8-K filed by CERo Therapeutics Holdings,
    Inc. with the Securities and Exchange Commission on February 6, 2025).

    4.2
     
    Form
    of Pre-Funded Warrant (incorporated by reference to Exhibit 4.8 to the Registration Statement on Form S-1/A filed by CERo Therapeutics
    Holdings, Inc. with the Securities and Exchange Commission on January 21, 2025).

    4.3
     
    Description
    of Securities (incorporated by reference to Exhibit 4.4 to the Current Report on Form S-1 filed by CERo Therapeutics Holdings, Inc.
    with the Securities and Exchange Commission on July 21, 2025).

    10.1+†
     
    Securities
    Purchase Agreement, dated as of April 21, 2025, by and between CERo Therapeutics Holdings, Inc. and the investors named therein (